JP2022541441A5 - - Google Patents

Info

Publication number
JP2022541441A5
JP2022541441A5 JP2022502275A JP2022502275A JP2022541441A5 JP 2022541441 A5 JP2022541441 A5 JP 2022541441A5 JP 2022502275 A JP2022502275 A JP 2022502275A JP 2022502275 A JP2022502275 A JP 2022502275A JP 2022541441 A5 JP2022541441 A5 JP 2022541441A5
Authority
JP
Japan
Prior art keywords
cells
derived
cell
car
mica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541441A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042657 external-priority patent/WO2021011919A1/en
Publication of JP2022541441A publication Critical patent/JP2022541441A/ja
Publication of JP2022541441A5 publication Critical patent/JP2022541441A5/ja
Priority to JP2025109951A priority Critical patent/JP2025157281A/ja
Pending legal-status Critical Current

Links

JP2022502275A 2019-07-17 2020-07-17 免疫エフェクター細胞操作およびその使用 Pending JP2022541441A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025109951A JP2025157281A (ja) 2019-07-17 2025-06-30 免疫エフェクター細胞操作およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962875490P 2019-07-17 2019-07-17
US62/875,490 2019-07-17
US202063021560P 2020-05-07 2020-05-07
US63/021,560 2020-05-07
PCT/US2020/042657 WO2021011919A1 (en) 2019-07-17 2020-07-17 Immune effector cell engineering and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025109951A Division JP2025157281A (ja) 2019-07-17 2025-06-30 免疫エフェクター細胞操作およびその使用

Publications (2)

Publication Number Publication Date
JP2022541441A JP2022541441A (ja) 2022-09-26
JP2022541441A5 true JP2022541441A5 (enExample) 2023-07-21

Family

ID=74211221

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502275A Pending JP2022541441A (ja) 2019-07-17 2020-07-17 免疫エフェクター細胞操作およびその使用
JP2025109951A Pending JP2025157281A (ja) 2019-07-17 2025-06-30 免疫エフェクター細胞操作およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025109951A Pending JP2025157281A (ja) 2019-07-17 2025-06-30 免疫エフェクター細胞操作およびその使用

Country Status (11)

Country Link
US (2) US20220275333A1 (enExample)
EP (1) EP3999628A4 (enExample)
JP (2) JP2022541441A (enExample)
KR (1) KR20220035190A (enExample)
CN (1) CN114258429A (enExample)
AU (1) AU2020314969A1 (enExample)
BR (1) BR112022000641A2 (enExample)
CA (1) CA3146967A1 (enExample)
IL (1) IL289830A (enExample)
MX (1) MX2022000553A (enExample)
WO (1) WO2021011919A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3181118A1 (en) * 2020-07-15 2022-01-20 Yali ZHOU Engineered immune cell for allotransplantation
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
CN117083375A (zh) * 2021-01-29 2023-11-17 艾洛基治疗公司 敲低或敲除TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP和RFXANK中的一个或多个以减轻同种异体细胞产物的T细胞识别
CN116897202A (zh) * 2021-02-24 2023-10-17 科济生物医药（上海）有限公司 Tigit工程化细胞及其组合物
WO2022179620A1 (zh) * 2021-02-25 2022-09-01 克莱格医学有限公司 Cd94工程化细胞及其组合物
CA3209946A1 (en) * 2021-03-05 2022-09-09 Matthew Angel Engineered immune cell therapies
CA3210702A1 (en) * 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
WO2022251443A1 (en) * 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
US20240307540A1 (en) * 2021-07-02 2024-09-19 Fate Therapeutics, Inc. Protected effector cells and use thereof for allogeneic adoptive cell therapies
CA3228865A1 (en) * 2021-08-18 2023-02-23 Bahram Valamehr Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with antibody
IL312565A (en) * 2021-11-08 2024-07-01 Fate Therapeutics Inc Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
US20250018034A1 (en) * 2021-11-08 2025-01-16 Fate Therapeutics, Inc. Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors
KR20250005097A (ko) * 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
US20260108554A1 (en) * 2022-05-01 2026-04-23 Factor Bioscience Inc. Methods for reprogramming and gene editing cells
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024047561A1 (en) * 2022-09-02 2024-03-07 Janssen Biotech, Inc. Biomaterials and processes for immune synapse modulation of hypoimmunogenicity
EP4593868A1 (en) * 2022-09-26 2025-08-06 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
CN119923264A (zh) * 2022-09-27 2025-05-02 基因泰克公司 抑制基因毒性应激以改善t细胞工程化
GB202218144D0 (en) * 2022-12-02 2023-01-18 Univ Oxford Innovation Ltd Product
CN120826463A (zh) * 2023-03-31 2025-10-21 杭州启函生物科技有限公司 使用工程化细胞的癌症免疫疗法
WO2025101471A1 (en) * 2023-11-09 2025-05-15 Merck Sharp & Dohme Llc Anti-cd27 antibody cell-based biological potency assay
CN118703438B (zh) * 2024-08-30 2025-01-14 星奕昂(上海)生物科技有限公司 一种活化和扩增自然杀伤细胞的方法及其用途
CN119220607B (zh) * 2024-12-03 2025-03-07 星奕昂(上海)生物科技有限公司 编辑tim3基因获得功能强化的car-nk细胞的方法与应用
CN119552808A (zh) * 2025-01-24 2025-03-04 上海元戊医学技术有限公司 通用型诱导多能干细胞及其制备方法与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
JP5328018B2 (ja) * 2006-06-05 2013-10-30 国立大学法人広島大学 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
CN113699159A (zh) 2014-03-28 2021-11-26 明尼苏达大学评议会 涉及经工程改造的cd16的多肽、细胞和方法
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
WO2016154585A1 (en) * 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CA3007473A1 (en) 2015-12-14 2017-06-22 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
EP3661552A4 (en) * 2017-05-22 2021-08-25 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR INHIBITING MICA / B REJECTION
AU2018359907A1 (en) * 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
US11639496B2 (en) * 2017-12-05 2023-05-02 Celyad S.A. Reducing fratricide of immune cells expressing NKG2D-based receptors
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas

Similar Documents

Publication Publication Date Title
JP2022550899A5 (enExample)
JP2022548943A5 (enExample)
JP2021505131A5 (enExample)
JP2022510207A5 (enExample)
JP2023505206A5 (enExample)
JP2023530704A5 (enExample)
US12404338B2 (en) Anti CD30 chimeric antigen receptor and its use
JP2023549098A5 (enExample)
JP2023548467A5 (enExample)
JP2021519061A5 (enExample)
JP7623020B2 (ja) 同種異系移植のための操作された免疫細胞
JP2023548829A5 (enExample)
KR102600544B1 (ko) 트랜스진 유전자 태그 및 사용 방법
JP2023153141A (ja) 治療免疫細胞の有効性を改良するための方法
Maher Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells
JP2023545992A5 (enExample)
KR20230129983A (ko) 조작된 세포 요법을 위한 표적화된 사이토카인 구축물
RS62870B1 (sr) Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
US10941202B2 (en) Isolated human mesenchymal stem cell expressing a bispecific antibody that binds CD33 and CD3 and method of using to treat cancer
JP2024502157A (ja) 樹状細胞活性化キメラ抗原受容体及びその使用
JP2024533375A5 (enExample)
JP2024515920A5 (enExample)
KR20210018838A (ko) 유전자 조작된 세포 및 응용
AU2021338819A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
JP2024525492A5 (enExample)